(firstQuint)A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia.

 Study design: Phase I/II study The Phase I study is open-label with four increasing dose levels for up to four 21-day cycles.

 Safety and activity will be evaluated at the end of each cycle.

 The Phase II study is open label with administration of the recommended phase dose of PTX-200 for up to four 21-day cycles.

 PTX-200 will be co-administered with cytarabine in both the Phase I and Phase II parts of the study.

.

 A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia@highlight

A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.

